2 unknown, 1 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow OncXerna Theraputics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer navicixizumab, Xerna™ TME Panel - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Unknown | OncXerna Theraputics, Inc. | 400 | 2022-11-30 | 2022-08-15 |
| A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy - Colorectal Cancer, Triple Negative Breast Cancer | Phase 2 | Unknown | OncXerna Theraputics, Inc. | 180 | 2022-08-05 | 2023-01-31 |
| An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients Bavituximab, Pembrolizumab Injection - Gastric Cancer, GastroEsophageal Cancer | Phase 2 | Completed | OncXerna Theraputics, Inc. | 80 | 2019-09-11 | 2023-02-08 |
Ovarian Neoplasms (2) · Stomach Neoplasms (2) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Triple Negative Breast Neoplasms (1)
bavituximab (1) · navicixizumab (1) · pembrolizumab (1)
United States (2) · South Korea (1) · Taiwan (1) · United Kingdom (1)
2019 (1)